Clinical meaning
Palliative chemotherapy is the administration of cytotoxic or targeted antineoplastic agents with the explicit goal of improving quality of life, managing symptoms, and potentially extending survival in patients with advanced or metastatic cancer that is not curable. This stands in contrast to curative chemotherapy, where the intent is to eliminate the cancer entirely and achieve long-term remission or cure. Understanding this distinction is fundamental because it changes the entire framework of care: in curative treatment, significant toxicity may be acceptable because the endpoint is cure; in palliative treatment, the benefit of tumor shrinkage must be weighed against the burden of treatment side effects, and the primary goal shifts from tumor eradication to comfort and quality of life. Chemotherapy works by interfering with cellular division and DNA replication. Because cancer cells divide more rapidly and uncontrollably than most normal cells, they are preferentially affected by chemotherapy. However, normal cells with high turnover rates are also damaged, producing the well-known side effects: bone marrow suppression (neutropenia, anemia, thrombocytopenia from damage to hematopoietic stem cells), mucositis and stomatitis (damage to rapidly dividing mucosal epithelium of the mouth and GI tract), alopecia (damage to rapidly dividing hair follicle cells), nausea and vomiting (chemotherapy triggers serotonin release from enterochromaffin cells in the GI tract, which activates 5-HT3 receptors on vagal afferent nerves, sending emetic signals to the chemoreceptor trigger zone in the medulla), and immunosuppression. In the palliative setting, symptom burden assessment becomes the central focus of nursing care. The Edmonton Symptom Assessment System (ESAS) is a validated tool that evaluates nine common cancer-related symptoms: pain, tiredness, nausea, depression, anxiety, drowsiness, appetite, well-being, and shortness of breath, each rated on a 0-10 scale. Quality of life instruments such as the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire) and the FACT-G (Functional Assessment of Cancer Therapy - General) provide comprehensive evaluation of physical, emotional, social, and functional well-being. The decision to initiate, continue, or discontinue palliative chemotherapy involves ongoing assessment of the risk-benefit balance: if the treatment causes more suffering than the disease symptoms it was intended to control, the treatment should be reconsidered. Performance status assessment using the Eastern Cooperative Oncology Group (ECOG) scale or the Karnofsky Performance Status (KPS) scale helps determine whether a patient is well enough to tolerate and potentially benefit from chemotherapy. Patients with ECOG performance status of 3-4 (in bed more than 50% of the day or completely bedbound) generally do not benefit from palliative chemotherapy and may be better served by symptom management alone. Informed consent for palliative chemotherapy requires particularly thorough discussion because the patient must understand that the treatment will not cure the cancer, the expected benefits in terms of symptom relief and potential survival extension, the likely side effects and their management, and the alternative of foregoing chemotherapy in favor of comfort-focused care (hospice). The practical nurse plays a vital role in reinforcing this education, assessing the patient's understanding, monitoring for treatment side effects, managing symptoms, and supporting the patient and family through the complex emotional journey of living with advanced cancer.